CMB International keeps RMB 204.54 target for Mindray stock
Published on 10/09/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- CMB International maintains a RMB 204.54 target for Mindray stock, according to a September 19, 2026 analysis.
- First-half 2026 revenue rose 6.00 percent to RMB 17.747 billion, while attributable net profit fell 5.37 percent.
- International revenue increased 13.67 percent and emerging-business revenue rose 19.59 percent in the first half of 2026.
- Mindray stock stood at CNY 161.40 on October 9, 2026, with a CNY 195.7 billion market capitalization.
CMB International maintained a RMB 204.54 target for Mindray stock, as EdgeChat reported on September 19, 2026. The target comes as Mindray's first-half results showed revenue growth returning while profit remained under pressure from currency effects.
Three dated signals shape the story
On August 31, 2026, Mindray proposed a cash distribution for the first half of 2026, according to Marketscreener. The proposal followed a difficult fiscal year 2025, when revenue fell 9.38 percent to RMB 33.282 billion and net profit declined 30.28 percent to RMB 8.136 billion.
On September 10, 2026, Huaxin Securities initiated coverage with a Buy rating, as Futubull reported. The note identified international revenue of RMB 9.471 billion in the first half of 2026, up 13.67 percent year on year, while domestic revenue fell 1.61 percent to RMB 8.276 billion.
On October 2, 2026, Mindray released its 2026 semi-annual report, according to iMedia. Revenue reached RMB 17.747 billion, up 6.00 percent year on year, while net profit attributable to shareholders fell 5.37 percent to RMB 4.797 billion.
What does overseas growth mean for margins?
The answer is mixed. In the first half of 2026, international revenue grew 13.67 percent, but profit growth lagged revenue growth as foreign-exchange losses affected the result. Huaxin Securities said the company recognized RMB 574 million in foreign-exchange losses during the period, while adjusted net profit excluding non-recurring items rose 11.08 percent year on year, according to Futubull. That split makes international expansion a growth engine, but currency and pricing pressure remain important variables for earnings.
Emerging businesses supplied another concrete growth signal. Revenue from those businesses rose 19.59 percent to RMB 3.110 billion in the first half of 2026, according to iMedia. The figure outpaced group revenue growth and gives the company a second expansion channel alongside overseas sales.
Stock price and valuation context
Mindray stock stood at CNY 161.40 on the Shenzhen Stock Exchange on October 9, 2026 at 3:04 p.m. CST, up 2.41 percent from CNY 157.60. Its market capitalization was CNY 195.7 billion, and the 52-week range was CNY 130.66 to CNY 247.00 on the same quote snapshot.
The market price remains below CMB International's RMB 204.54 target cited by EdgeChat on September 19, 2026, but the target is an analyst view rather than a guaranteed outcome. Mindray's first-half revenue improvement therefore sits alongside a clear earnings-quality question: how quickly can overseas and emerging-business growth offset currency and domestic pricing pressure?
Mindray stock facts
- Company: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- ISIN: CNE100003G67
- Ticker: 300760
- Primary exchange: Shenzhen Stock Exchange ChiNext
- Price Shenzhen Stock Exchange (as of October 9, 2026, 3:04 p.m. CST): CNY 161.40
- Change versus prior close: plus 2.41 percent
- Prior close Shenzhen Stock Exchange (October 8, 2026): CNY 157.60
- Market capitalization: CNY 195.7 billion (as of October 9, 2026)
- 52-week range: CNY 130.66-CNY 247.00 (as of October 9, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report Shanghai Composite.
